Patents by Inventor Mark Searcey

Mark Searcey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synthesis of duocarmycin analogues
    Patent number: 9765077
    Abstract: A novel Fmoc protected duocarmycin subunit and utilization as a reagent in solid phase protein synthesis methodology. Also provided is a novel method of solid phase peptide synthesis, and in particular a method for the production of novel intermediates and novel monomeric and extended duocarmycin analogues having amino acid substituents.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: September 19, 2017
    Assignee: University of East Anglia
    Inventors: Michael J Stephenson, Lesley A Howell, Mark Searcey
  • Synthesis of Duocarmycin Analogues
    Publication number: 20160347753
    Abstract: A novel Fmoc protected duocarmycin subunit and utilisation as a reagent in solid phase protein synthesis methodology. Also provided is a novel method of solid phase peptide synthesis, and in particular a method for the production of novel intermediates and novel monomeric and extended duocarmycin analogues having amino acid substituents.
    Type: Application
    Filed: May 29, 2015
    Publication date: December 1, 2016
    Inventors: Michael J Stephenson, Lesley A Howell, Mark Searcey
  • Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment
    Patent number: 8017640
    Abstract: Compounds of the general formula (I) or (IA) in which X is H, Y is a leaving group, R1 preferably being an aromatic DNA binding subunit are prodrug analogues of duocarmycin. The compounds are expected to be hydroxylated at the carbon atom to which C is joined, by cytochrome P450, in particular by CYP1B1, expressed at high levels in tumors. The prodrug is expected to be activated preferentially in tumor cells, which it will act as a DNA alkylating agent preventing cell division.
    Type: Grant
    Filed: February 27, 2007
    Date of Patent: September 13, 2011
    Assignee: University of Bradford
    Inventors: Mark Searcey, Laurence Hylton Patterson
  • Pyrrolo-indole and pyrrolo-quinoline derivatives as prodrugs for tumour treatment
    Patent number: 7626026
    Abstract: Compounds of the general formula (I) or (IA) in which X is H, Y is a leaving group, R1 and optionally also R3 preferably being an aromatic DNA binding subunit are prodrug analogues of duocarmycin. The compounds are expected to be hydroxylated at the carbon atom to which X is joined, by cytochrome P450, in particular by CYP1B1, expressed at high levels in tumors. The prodrug is expected to be activated preferentially in tumor cells, where it will act as a DNA alkylating agent preventing cell division.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: December 1, 2009
    Assignee: University of Bradford
    Inventors: Mark Searcey, Laurence Hylton Patterson
  • Analogues of the Azinomycins as Anti-Tumour Agents and as Prodrugs
    Publication number: 20090233966
    Abstract: Compounds of general formula (I) or a salt thereof in which R1 is preferably an aromatic DNA binding subunit are oxidation-activated prodrugs. The compounds are expected to be converted into an epoxide at the alkene to which R2 is attached by cytochrome P450, in particular CYPIBI, expressed at high levels in tumours. R3 preferably comprises a Nitrogen mustard to provide a prodrug which has 2 alkylating groups. The prodrugs are expected to be activated preferentially in tumour cells.
    Type: Application
    Filed: March 16, 2006
    Publication date: September 17, 2009
    Applicant: School of Pharmacy, University of London
    Inventors: Mark Searcey, Laurence Hylton Patterson, Klaus Pors, Maxwell Casely-Hayford
  • Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment
    Publication number: 20070161669
    Abstract: Compounds of the general formula (I) or (IA) in which X is H, Y is a leaving group, R1 preferably being an aromatic DNA binding subunit are prodrug analogues of duocarmycin. The compounds are expected to be hydroxylated at the carbon atom to which C is joined, by cytochrome P450, in particular by CYP1B1, expressed at high levels in tumours. The prodrug is expected to be activated preferentially in tumour cells, which it will act as a DNA alkylating agent preventing cell division.
    Type: Application
    Filed: February 27, 2007
    Publication date: July 12, 2007
    Inventors: Mark Searcey, Laurence Patterson
  • Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment
    Patent number: 7192977
    Abstract: Compounds of the general formula (I) or (IA) in which X is H, Y is a leaving group, R1 preferably being an aromatic DNA binding subunit are prodrug analogues of duocarmycin. The compounds are expected to be hydroxylated at the carbon atom to which X is joined, by cytochrome P450, in particular by CYP1B1, expressed at high levels in tumors.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: March 20, 2007
    Assignee: School of Pharmacy
    Inventors: Mark Searcey, Laurence Hylton Patterson
  • Indoline and tetrahydro-quinolines as prodrugs for tumour treatment
    Patent number: 7179921
    Abstract: Compounds of the general formula I or IA or a salt in which X is H, Y is a leaving group, R1 preferably being an aromatic DNA binding subunit are prodrug analogues of duocarmycin. The compounds are expected to be hydroxylated at the carbon atom to which X is joined, by cytochrome P450, in particular by CYP1B1, expressed at high levels in tumours.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: February 20, 2007
    Assignee: School of Pharmacy, University of London
    Inventors: Mark Searcey, Laurence Hylton Patterson
  • Pyrrolo-indole and pyrrolo-quinoline derivatives as prodrugs for tumour treatment
    Publication number: 20040157873
    Abstract: Compounds of the general formula (I) or (IA) in which X is H, Y is a leaving group, R1 and optionally also R3 preferably being an aromatic DNA binding subunit are prodrug analogues of duocarmycin. The compounds are expected to be hydroxylated at the carbon atom to which X is joined, by cytochrome P450, in particular by CYP1B1, expressed at high levels in tumours. The prodrug is expected to be activated preferentially in tumour cells, where it will act as a DNA alkylating agent preventing cell division.
    Type: Application
    Filed: April 6, 2004
    Publication date: August 12, 2004
    Inventors: Mark Searcey, Laurence Hylton Patterson
  • Indoline and tetrahydro-quinolines as prodrugs for tumour treatment
    Publication number: 20040157880
    Abstract: Compounds of the general formula I or IA or a salt in which X is H, Y is a leaving group, R1 preferably being an aromatic DNA binding subunit are prodrug analogues of duocarmycin. The compounds are expected to be hydroxylated at the carbon atom to which X is joined, by cytochrome P450, in particular by CYP1B1, expressed at high levels in tumours. The prodrug is expected to be activated preferentially in tumour cells, where it will act as a DNA alkylating agent preventing cell division.
    Type: Application
    Filed: March 29, 2004
    Publication date: August 12, 2004
    Inventors: Mark Searcey, Laurence Hylton Patterson
  • Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment
    Publication number: 20040138246
    Abstract: Compounds of the general formula (I) or (IA) in which X is H, Y is a leaving group, R1 preferably being an aromatic DNA binding subunit are prodrug analogues of duocarmycin. The compounds are expected to be hydroxylated at the carbon atom to which X is joined, by cytochrome P450, in particular by CYP1B1, expressed at high levels in tumours. The prodrug is expected to be activated preferentially in tumour cells, where it will act as a DNA alkylating agent preventing cell division.
    Type: Application
    Filed: February 13, 2004
    Publication date: July 15, 2004
    Inventors: Mark Searcey, Laurence Hylton Patterson